RT Journal Article
SR Electronic
T1 Age-Related Macular Degeneration, Cardiovascular Disease and Stroke
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263389
DO 10.1101/2021.09.13.21263389
A1 Gerardo Ledesma-Gil
A1 Oscar Otero-Marquez
A1 Sharmina Alauddin
A1 Yuehong Tong
A1 Wei Wei
A1 Katy Tai
A1 Harriet Lloyd
A1 Micaela Koci
A1 Catherine Ye
A1 Cinthi Pillai
A1 Maria Scolaro
A1 Arun Govindaiah
A1 Alauddin Bhuiyan
A1 Avnish Deobhakta
A1 Richard B. Rosen
A1 Lawrence A. Yannuzzi
A1 K. Bailey Freund
A1 R. Theodore Smith
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263389.abstract
AB Importance High-risk vascular diseases (HRVs) may remain undetected until catastrophe ensues. Detection from non-invasive retinal imaging would be highly significant.Objective To demonstrate that certain lesions of Age-Related Macular Degeneration (AMD) found on retinal imaging correlate with co-existing HRVs.Design Cross-sectional cohort study. Two years. Retinal image graders blinded to HRV status.Setting 2 retina referral clinics.Participants 151 consecutive AMD patients, ages 50-90, 97 females, 54 males, with lesions of soft drusen and/or subretinal drusenoid deposits (SDD). 12 others approached, 10 refused, 2 excluded.Methods Patients were classified by retinal imaging into SDD (SDD present, +/- drusen) or nonSDD (soft drusen only), and by history into HRV (cardiac pump defect (myocardial infarction (MI), coronary artery bypass grafting (CABG), congestive heart failure (CHF)), valve defect, and carotid stroke) or nonHRV, with serum risk factors and medical histories.Main Outcome Measures Correlations of HRV with SDD and other covariates (Univariate chi-square and multivariate regression). Performance of Machine Learning predicting HRV.Results 75 SDD subjects; 76 nonSDD subjects; HRV prevalence 19.2% (29/151).High density lipoprotein (HDL) < 62 mg/Dl was found in 24/29 HRV, 42/122 nonHRV, OR 12.40, 95% Confidence Interval (CI) 5.125-30.014; p= 0.0002.15 Pump defects, 14/15 SDD, 8 Valve defects, 6/8 SDD (4 severe aortic stenosis), 6 carotid strokes, 5/6 SDD. Total HRVs 29, 25/29 SDD, OR 9.0, 95% CI 2.95-27.46; p= 0.000012.Adjusted multivariate correlations. HRV with SDD (p= 0.000333). SDD and HDL < 62 with HRV (p= 0.000098 and 0.021).Machine Learning prediction of HRVs from SDD status and HDL level: specificity 87.4%, sensitivity 77.4%, accuracy 84.9%; 95% CIs(%) 79.0-93.3, 58.0-90.4, 77.5-90.7, respectively.Conclusions and Relevance High-risk vascular diseases were accurately identified in a cohort of AMD patients from the presence of characteristic deposits (SDDs) on imaging and HDL levels. The SDDs are directly consequent to inadequate ocular perfusion resulting from the systemic vasculopathies. Further validation in larger cohorts of both vasculopathic and AMD subjects could bring this system into widespread medical practice, to reduce mortality and morbidity from vascular disease, particularly in women, where undiagnosed cardiac disease remains a serious issue.Question What is the relationship and driving mechanism between High Risk Vascular Diseases (HRVs) and Age-Related Macular Degeneration (AMD)?Findings The specific AMD lesions of Subretinal Drusenoid Deposits (SDDs) were found to be highly correlated with and directly consequent to the inadequate ocular perfusion resulting from the HRVs of severe cardiac pump insufficiency or valve defect, and carotid occlusion, These vasculopathies could be predicted from the presence of SDDs on spectral domain optical coherence tomography (SD-OCT) imaging and serum HDL.Meaning Screening for SDDs with SD-OCT imaging could reduce mortality and morbidity from severe vascular disease, particularly in women, where undiagnosed cardiac disease remains a serious issue.Competing Interest StatementRichard B. Rosen is a consultant to OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer, Diopsys and Teva. He has personal financial interests in Opticology, Guardion and CellView. K. Bailey Freund is a consultant to Regeneron, Allergan, Zeiss, Bayer, Heidelberg Engineering and Novartis. He receives research funding from Genentech/Roche. R Theodore Smith is a consultant to Ora Technologies. The remaining authors have no relevant disclosures.Clinical TrialNCT04087356Funding StatementRegeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent Blindness Challenge Grant, Macula Foundation (KBF), Bayer-Global Ophthalmology Awards (GLG), International Council of Ophthalmology-Alcon Fellowship (OOM), New York Eye and Ear Infirmary Foundation (SA).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent Blindness Challenge Grant, Macula Foundation (KBF), Bayer-Global Ophthalmology Awards (GLG), International Council of Ophthalmology-Alcon Fellowship (OOM), New York Eye and Ear Infirmary Foundation (SA). This was a multicenter prospective study conducted at two tertiary vitreoretinal referral centers in New York City, USA: Vitreous Retina Macula Consultants of New York (LY, KBF), and Department of Ophthalmology, New York Eye and Ear Infirmary of Mount Sinai School of Medicine (MSSM) (RBR, RTS), from January 2019 to January 2021. The institutional review board of MSSM approved the study, which adhered to the tenets of the Declaration of Helsinki. ClinicalTrials.gov Identifier: NCT04087356.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A